Results 1 to 10 of about 1,009 (151)

Venetoclax in the Therapeutic Strategy for BPDCN Management [PDF]

eJHaem
Background Venetoclax, a B‐cell lymphoma 2 (BCL‐2) inhibitor, is a promising treatment for blastic plasmacytoid dendritic cell neoplasm (BPDCN) and is currently under evaluation in clinical trials.
Margaux Poussard, Maxime Fredon, Imane Belakri, Sabeha Biichle, Florian Renosi, Evan Seffar, Morgane Boichut, Romain Boidot, Elodie Bôle‐Richard, Francis Bonnefoy, Marie Kroemer, Sophie Bonnot‐Perrin, Philippe Saas, Olivier Adotévi, Francine Garnache‐Ottou, Fanny Angelot‐Delettre   +15 more
doaj   +5 more sources

Blastic plasmacytoid dendritic cell neoplasm secondary to acute myeloid leukemia with shared mutations in TET2 and DNMT3A: a case report and literature review [PDF]

Frontiers in Immunology
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive hematologic malignancy. Recent studies have highlighted its occurrence in patients with a history of preceding myeloid neoplasms.
Yao Sun, Yingjie Liu, Na Liu, Xiaohui Zhang, Wenrong Huang, Liangding Hu   +5 more
doaj   +2 more sources

Multi-organ single-cell analysis reveals PLD4 as a biomarker and potential therapeutic target of blastic plasmacytoid dendritic cell neoplasm [PDF]

Cancer Cell International
Background Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematological malignancy originating from precursors of plasmacytoid dendritic cells.
Meng Wang, Xiaotong Xue, Zhenzhen Wang, Chuan Wang, Gongqi Yu, Zihao Mi, Xu Sang, Jianwen Wang, Yongxia Liu, Xuechao Chen, Shengli Chen, Guizhi Zhou, Hong Liu, Hao Chen, Yonghu Sun, Furen Zhang   +15 more
doaj   +2 more sources

Real-world management of blastic plasmacytoid dendritic cell neoplasm at an academic center with a broad regional referral base [PDF]

Leukemia Research Reports
BPDCN is an aggressive myeloid malignancy characterized by unique expression of CD123, CD4, CD56, CD303, CD304, TCL1 and TCF4. The development of tagraxofusp, a CD123-directed cytotoxin, has revolutionized BPDCN treatment, especially for patients unfit ...
Nathan M. Krah, Rasmus Hoeg, Paul J. Shami, Shannon E. Elf, Lauren E. Lee, Naveen Pemmaraju, Ami B. Patel   +6 more
doaj   +2 more sources

BPDCN: When polychemotherapy does not compromise allogeneic CD123 CAR‐T cell cytotoxicity [PDF]

eJHaem, 2021
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematological malignancy with poor prognosis and no treatment consensus. Combining chemotherapy and immunotherapy is a promising strategy to enhance therapeutic effect. Before combining these
Margaux Poussard, Laure Philippe, Maxime Fredon, Elodie Bôle‐Richard, Sabeha Biichle, Florian Renosi, Sophie Perrin, Marie Kroemer, Samuel Limat, Francis Bonnefoy, Etienne Daguindau, Eric Deconinck, Bérengère Gruson, Philippe Saas, Olivier Adotévi, Francine Garnache‐Ottou, Fanny Angelot‐Delettre   +16 more
doaj   +3 more sources

Petechiae and a Persistent Violaceous Nodule: A Presentation of Blastic Plasmacytoid Dendritic Cell Neoplasm to Dermatology [PDF]

Case Reports in Dermatological Medicine
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare, highly aggressive CD4+ CD56+ hematopoietic malignancy. The cutaneous presentation is variable but often includes violaceous nodules.
Madison Anzelc, Christina Druskovich, Austin Cusick, Matthew Franklin   +3 more
doaj   +2 more sources

Early detection of transformation to BPDCN in a patient with MDS [PDF]

Experimental Hematology & Oncology, 2018
Background Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive hematologic malignancy characterized by neoplastic cells that are positive for CD123, CD4, BDCA2, and TCL1 and aberrant expression of CD56.
Kamal Chamoun, Sanam Loghavi, Naveen Pemmaraju, Marina Konopleva, Michael Kroll, Madeleine Nguyen-Cao, Marisa Hornbaker, Courtney D. DiNardo, Tapan Kadia, Jeffrey Jorgensen, Michael Andreeff, Shimin Hu, Christopher B. Benton   +12 more
doaj   +3 more sources

Blastic plasmacytoid dendritic cell neoplasm (BPDCN): international, multi-center collaboration and global registry program [PDF]

Discover Oncology
Background Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) is a rare and aggressive hematologic malignancy originating from plasmacytoid dendritic cell precursors.
Astghik Voskanyan, Maria Badikyan, Marina Konopleva, Alvaro Alencar, Arusyak Ivanyan, Carolyn Owen, Consolato M. Sergi, Ching-Tien Peng, Dickran Kazandjian, Justin Taylor, Funda Tekkesin, Hasanein Ghali, Karen Bedirian, Maria Paola Martelli, Enrico Attardi, Maria Teresa Voso, Mariam Abramashvili, Mazin Faisal Al-Jadiry, Michalis Michael, Min-Yu Su, Nare Martirosyan, Nerses Ghahramanyan, Nino Totogashvili, Pavel P. Kotoucek, Rejin Kebudi, Robin Ohannessian, Ruzanna Papyan, Shushan Hovsepyan, Salma Elashwah, Sameer Bakhshi, Samvel Bardakhchyan, Samvel Danelyan, Shaimaa El-Ashwah, Tezer Kutluk, Deniz Tuğcu, Ahmad Alhuraiji, Vassilios Lazaris, Gevorg Tamamyan, Naveen Pemmaraju   +38 more
doaj   +2 more sources

BPDCN: state of the art. [PDF]

Hematology Am Soc Hematol Educ Program
Abstract The emergence of blastic plasmacytoid dendritic cell neoplasm (BPDCN) as its own distinct entity within the pantheon of hematologic malignancies is due to the growing understanding of its unique multiorgan clinical presentation and characteristic skin lesions. The occurrence of BPDCN is generally heralded by a multicompartmental
Pemmaraju N.
europepmc   +3 more sources

BPDCN MYB fusions regulate cell cycle genes, impair differentiation, and induce myeloid–dendritic cell leukemia [PDF]

JCI Insight
MYB fusions are recurrently found in select cancers, including blastic plasmacytoid DC neoplasm (BPDCN), an acute leukemia with poor prognosis. They are markedly enriched in BPDCN compared with other blood cancers and, in some patients, are the only ...
Christopher A.G. Booth, Juliette M. Bouyssou, Katsuhiro Togami, Olivier Armand, Hembly G. Rivas, Kezhi Yan, Siobhan Rice, Shuyuan Cheng, Emily M. Lachtara, Jean-Pierre Bourquin, Alex Kentsis, Esther Rheinbay, James A. DeCaprio, Andrew A. Lane   +13 more
doaj   +2 more sources